Knockdown of integrin α3β1 expression induces proliferation and migration of non-small cell lung cancer cells

Oncology Reports

Volumn 29, Issue 2, 2013, Pages 662-668

  Yoon, Hyun Jae ^a   Cho, Young Rak ^b   Joo, Ji Hye ^b   Seo, Dong Wan ^b  

^a Quality Management Department   (South Korea)

^b Dankook University   (South Korea)

Author keywords

EGFR; Integrin 3 1; Lung cancer; NF B; P53

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; VERY LATE ACTIVATION ANTIGEN 3;

ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME LOCALIZATION; GENE SILENCING; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

CARCINOMA, NON-SMALL-CELL LUNG; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASES; HUMANS; INTEGRIN ALPHA3BETA1; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84872810441     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2169     Document Type: Article

References (35)

1. Cox D, Brennan M and Moran N: Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov 9: 804-820, 2010.
2. Hood JD and Cheresh DA: Role of integrins in cell invasion and migration. Nat Rev Cancer 2: 91-100, 2002. (Pubitemid 37328796)
3. Hynes RO: Integrins: bidirectional, allosteric signaling machines. Cell 110: 673-687, 2002. (Pubitemid 35283958)
4. Eliceiri BP: Integrin and growth factor receptor crosstalk. Circ Res 89: 1104-1110, 2001. (Pubitemid 34627867)
5. Desgrosellier JS and Cheresh DA: Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10: 9-22, 2010.
6. Kreidberg JA: Functions of α3β1 integrin. Curr Opin Cell Biol 12: 548-553, 2000.
7. Barr LF, Campbell SE, Bochner BS and Dang CV: Association of the decreased expression of α3β1 integrin with the altered cell: environmental interactions and enhanced soft agar cloning ability of c-myc-overexpressing small cell lung cancer cells. Cancer Res 58: 5537-5545, 1998. (Pubitemid 28551142)
8. Adachi M, Taki T, Huang C, et al: Reduced integrin α3 expression as a factor of poor prognosis of patients with adenocarcinoma of the lung. J Clin Oncol 16: 1060-1067, 1998. (Pubitemid 28108741)
9. Lemmon MA and Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 141: 1117-1134, 2010.
10. Sharma SV, Bell DW, Settleman J and Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181, 2007
11. Hynes NE and Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354, 2005 (Pubitemid 40637826)
12. Perkins ND: The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer 12: 121-132, 2012.
13. Kim YK, Lee EK, Kang JK, et al: Activation of NF-κB by HDAC inhibitor apicidin through Sp1-dependent de novo protein synthesis: its implication for resistance to apoptosis. Cell Death Differ 13: 2033-2041, 2006. (Pubitemid 44742686)
14. Cho Y-R, Choi S and Seo D-W: Sepiapterin regulates cell proliferation and migration: its association with integrin α3β1 and p53 in human lung cancer cells. Genes Genom 33: 577-582, 2011.
15. Seo D-W, Li H, Qu C-K, et al: Shp-1 mediates the anti proliferative activity of tissue inhibitor of metalloproteinase-2 in human microvascular endothelial cells. J Biol Chem 281: 3711-3721, 2006. (Pubitemid 43845989)
16. Kim S, Cho Y-R, Kim M-D, Kim H, Choi S and Seo D-W: Inhibitory effects of sepiapterin on vascular endothelial growth factor-A-induced proliferation and adhesion in human umbilical vein endothelial cells. Arch Pharm Res 34: 1571-1577, 2011.
17. S6K-dependent VEGFR-2 expression. Oncol Rep 26: 861-867, 2011.
18. Seo D-W, Kim SH, Eom S-H, et al: TIMP-2 disrupts FGF-2-induced downstream signaling pathways. Microvasc Res 76: 145-151, 2008.
19. Hong SY, Cho JY and Seo D-W: Ginsenoside Rp1 inhibits proliferation and migration of human lung cancer cells. Biomol Ther 19: 411-418, 2011.
20. Hodivala-Dilke KM, DiPersio CM, Kreidberg JA and Hynes RO: Novel roles for α3β1 integrin as a regulator of cytoskeletal assembly and as a trans-dominant inhibitor of integrin receptor function in mouse keratinocytes. J Cell Biol 142: 1357-1369, 1998. (Pubitemid 28429116)
21. Gogali A, Charalabopoulos K and Constantopoulos S: Integrin receptors in primary lung cancer. Exp Oncol 26: 106-110, 2004
22. Sherr CJ: The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 60: 3689-3695, 2000. (Pubitemid 32204552)
23. Mayo MW, Denlinger CE, Broad RM, et al: Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-κB through the Akt pathway. J Biol Chem 278: 18980-18989, 2003. (Pubitemid 36799282)
24. Stetler-Stevenson WG and Seo D-W: TIMP-2: an endogenous inhibitor of angiogenesis. Trends Mol Med 11: 97-103, 2005 (Pubitemid 40348986)
25. DiPersio CM, Shao M, Di Costanzo L, Kreidberg JA and Hynes RO: Mouse keratinocytes immortalized with large T antigen acquire α3β1 integrin-dependent secretion of MMP-9/gelatinase B. J Cell Sci 113: 2909-2921, 2000.
26. Heckman C, Mehew J and Boxer L: NF-κB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene 21: 3898-3908, 2002. (Pubitemid 34620858)
27. Lee HH, Dadgostar H, Cheng Q, Shu J and Cheng G: NF-κB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci USA 96: 9136-9141, 1999 (Pubitemid 29374720)
28. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
29. Stipp CS: Laminin-binding integrins and their tetraspanin partners as potential antimetastatic targets. Expert Rev Mol Med 12: e3, 2010.
30. Yoshimasu T, Sakurai T, Oura S, et al: Increased expression of integrin α3β1 in highly brain metastatic subclone of a human non-small cell lung cancer cell line. Cancer Sci 95: 142-148, 2004 (Pubitemid 38404315)
31. Seo D-W, Li H, Guedez L, et al: TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 114: 171-180, 2003. (Pubitemid 36936911)
32. Seo D-W, Saxinger WC, Guedez L, Cantelmo AR, Albini A and Stetler-Stevenson WG: An integrin-binding N-terminal peptide region of TIMP-2 retains potent angio-inhibitory and anti-tumorigenic activity in vivo. Peptides 32: 1840-1848, 2011.
33. Morello V, Cabodi S, Sigismund S, et al: β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells. Oncogene 30: 4087-4096, 2011.
34. Biswas DK and Iglehart JD: Linkage between EGFR family receptors and nuclear factor kappaB (NF-κB) signaling in breast cancer. J Cell Physiol 209: 645-652, 2006. (Pubitemid 44665682)
35. Fuster JJ, Sanz-González SM, Moll UM and Andrés V: Classic and novel roles of p53: prospects for anticancer therapy. Trends Mol Med 13: 192-199, 2007 (Pubitemid 46687126)